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Precision Medicine in Oncology: In Vitro Drug Sensitivity
and Resistance Test (DSRT) for Selection of Personalized
Anticancer Therapy
Anna A. Popova* and Pavel A. Levkin*
Precision or personalized medicine aims to determine an optimal therapy for
each individual patient. In oncology techniques such as next generation
sequencing, mRNA-sequencing, ChIP-sequencing, and mass spectrometry are
used to perform a full molecular profiling for each patient. However, it is not
always possible to determine a suitable treatment for an individual cancer
based on molecular profiling, mostly due to the high level of tumor
heterogeneity. In vitro drug sensitivity and resistance test (DSRT) can be
performed on cancer cells or tissues obtained from a patient with a panel of
anticancer compounds in order to experimentally define sensitivity and
resistance of each individual cancer. In combination with molecular profiling,
DSRT can provide a fuller picture about the nature of disease, allowing for
finding more appropriate therapy for each individual patient. In this progress
report, studies describing in vitro DSRTs on 2D and 3D cell models based on
patient-derived cells are reviewed and challenges and future steps needed for
the adaptation of these systems in clinics are discussed.
1. Cancer and its Current Treatment
Cancer is a disorder characterized by uncontrollable overgrowth
of usually one particular cell type, which becomes a cancer cell,
and by spreading of these cancer cells to lymph nodes and other
organs of the body, what is called metastatic disease. Tissue, and
in case of cancer, tumor microenvironment plays a crucial role in
the process of growth and spreading of cancer cells in the body.[1]
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Cancer is an incurable disease in many
cases with survival rate for >5 years rang-
ing from 98% for testicular cancer, 90% for
breast cancer, 65% for cervical cancer, 35%
for lung cancer, and only 5% for pancreatic
cancer,[2] making cancer the second leading
cause of death worldwide after cardiovascu-
lar diseases”[3] Along with surgical removal
of a tumor or radiation treatments, cancer
is treated with chemo- and targeted ther-
apy. Chemotherapeutic drugs are generally
toxic for all cells of the body, withmajority of
drugs affecting rapidly dividing cells, there-
fore being more toxic for cancer cells com-
pared to healthy ones.[4] However, for such
frequently dividing cells as hematopoietic
cells, cells of hair follicles, and cells lining
the mouth, stomach, and intestines such
drugs can be equally toxic.
Targeted therapy targets specific
biomarkers, usually proteins, that cause
uncontrollable growth of cancer cells.[5] Big part of targeted
agents are small molecules and inhibitors, which mostly inhibit
different kinases. Examples of such inhibitors include imatinib
(Gleevec), an inhibitor of kinase BCR-Abl, a fused oncogene
causing tumorigenesis in chronicmyelogenous leukemia; vemu-
rafenib (Zelboraf), dabrafenib (Tafinlar), and LGX818 (Braftovi)
are inhibitors of mutated B-RAF, a serine/threonine-specific pro-
tein kinase causing 70% of melanoma;[6] and Gefitinib (Iressa®),
which inhibits mutated epidermal growth factor receptor (EGFR)
and used for treatment of breast, lung, and other cancers.[7]
Another type of targeted agents includes monoclonal anti-
bodies, designed to attach to proteins and stimulate the im-
mune response in the body to eliminate tumor cells express-
ing those proteins. Some examples of such antibodies include
Trastuzumab (Herceptin), an antibody for Human Epidermal
Growth Factor Receptor 2 (HER2), which is overexpressed in
some breast cancers;[8] and Cetuximab (Erbitux)—a chimeric
(mouse/human) monoclonal antibody against EGFR and used
against colorectal, non-small cell lung and head/neck cancers.[9]
Targeted delivery of cancer therapeutics can be considered as
another type of targeted therapy. In this approach, anticancer
drugs are usually packed in nanocarries (NCs).[10,11] NCs aim to
increase efficiency of drug delivery to tumor sites, improve sta-
bility and solubility of drugs and in some cases improve thera-
peutic efficacy of the drug. There are NCs that “passively” target
tumor cites, meaning that they passively accumulate in tumor
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tissue due to the higher permeability of blood vessels in tumor
site (“enhanced permeability and retention (EPR) effect”).[12] An-
other type of NCs functionalized with affinity ligands specific for
cancer cells or tumor environment are designed to “actively” tar-
get tumors.[11]
2. Concept of Precision Medicine
Precision or personalized medicine aims to determine an opti-
mal therapy for each individual patient. Personalized medicine
emerged in early 2000s and is focusing on finding a suitable
therapy for each patient by allocating a patient to a particular
subgroup based on his/her characteristics, which determine to
which therapy a patient will most likely respond.[13] The term
“precision medicine” came first in 2009 and is used to define
a treatment for each individual patient, usually using modern
molecular tools as genomic profiling.[13] Precision medicine can
also extend to developing an individual treatment for each pa-
tient, for example, CAR-T cell therapy.[14] Both concepts overlap
in practice and often used interchangeably. In this review, we are
going to use the term “precision medicine” due to its more mod-
ern and broader meaning. The concept of precision medicine is
starting to be implemented for various disease types including
cardiovascular disorders,[15] Alzheimer’s disease,[16] diabetes,[17]
and oncology.[18] Choice of precision treatment is often based on
genetic profile, as well as other molecular profiling, of individ-
ual patient. Such profiling can give information about the cause,
type, and stage of disease, helping to find optimal treatment for
each individual patient, which is an ultimate goal of precision
medicine.
3. Personalizing Cancer Treatment
In oncology techniques such as next generation sequencing
(NGS), mRNA-sequencing, ChIP-sequencing, and mass spec-
trometry (MS) are used to determine individual profile of each
patient and a tumor. Along with performing targeted sequenc-
ing to find known mutations that can be treated by existing anti-
cancer drugs, it is possible now to perform full molecular pro-
filing for each individual patient. Such molecular profiling in-
cludes genomic, transcriptomic, proteomic, metabolomic, and
epigenomic analysis. The goal of “omic” analysis for cancer pa-
tients is to identify known variations in genome, epigenome,
transcriptome, or metabolome present in the patients that can
be predictive of their response to a therapy.[19–22] Pharmacoge-
nomics is a branch of genetics, which studies the correla-
tion between sensitivity or resistance of individual tumor to a
drug and genetic background of a patient. For example, pres-
ence of particular Single Nucleotide Polymorphisms (SNP) in
genome can predict response of a patient to a therapy.[23] Nu-
merous projects have been focused on collecting databases of
“omic” data, as well as software tools, and making them avail-
able for public use.[24] Examples of biggest projects are Can-
cer Genome Atlas (TCGA), collecting genetic mutations caus-
ing cancer; Human Proteome Project (HPP) documenting all of
the proteins of healthy human body; and International Human
Epigenome Consortium (IHEC) generating human epigenomes
from different types of healthy and disease-related human cells.
Using such databases in combination with statistical and in-
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formatics algorithms, the response of individual patients to a
therapy can be predicted with certain probability based onmolec-
ular profile of a patient.[19,25–27]
Despite all these advances in individualized therapy in oncol-
ogy, cancer still remains an incurable disease. There are sev-
eral reasons for it. First, not all tumors carry a mutation that
can be targeted with existing drugs. In a study covering se-
quencing of more than 3000 tumors from 26 types of cancer,
it was demonstrated that only quarter of analyzed tumors con-
tained knownmutation previously associated with cancer.[28] Sec-
ond, our knowledge about cancer mechanisms and databases on
“omic” data are still limited. Therefore, we cannot always draw
a conclusion regarding a choice of therapy based only on corre-
lation of biomarkers. Additional challenge of full molecular pro-
filing of individual patients is its limited applicability in clinics.
These tests are usually not covered by insurance companies, leav-
ing the costs of such tests to patients. The third andmajor reason
for cancer being difficult to cure is its very high heterogeneity.
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Cancer includes >200 different disease entities,[29] each of which
possesses high level of intratumor (occurring in one patient) and
intertumor (occurring between patients) heterogeneity.[30] The
total amount of mutations in one breast cancer can exceed 1000,
one-tenth of which can be unique to a particular tumor and not
occur in other breast cancers.[31] Moreover, a single tumor can
occur from cells with different driving mutations. Kandoth et al.,
in their study on comparison of mutational landscape of 12 ma-
jor cancer types, revealed that on average two to six driver mu-
tations occur per individual.[32] Similarly, Stephens et al. in their
study of mutational processes in 100 breast cancers found 40 dif-
ferent mutated genes in 73 different combinations with a num-
ber of driver mutations ranging from one to six per patient.[33]
In addition, each tumor becomes more diverse during its pro-
gression. This was clearly demonstrated in a study on genomic
analysis of single cancer cells derived from a single tumor[34] and
in the work of Kreso et al. describing profile of ten human col-
orectal cancers through serial xenograft passages inmice for mu-
tational analysis and response to chemotherapy.[35] Clonal evolu-
tion of tumors was also demonstrated in a work by Ding et al.,
where authors compared sequence of the primary and relapse
tumors from eight acute myeloid leukemia (AML) patients, and
demonstrated high rate of newly appeared mutations compared
with the original clone.[36] Numerous studies revealed that high
number of patients had mutations in their metastasis that were
not found in the original tumor.[34,37] Frequency of appearance of
new mutations depends on different individual internal (overall
somatic mutational frequencies) and external (etiology) factors.
For example, head and neck squamous cell tumors carry higher
number of mutations when caused by tobacco, compared with
tumors caused by human papilloma virus (HPV).[38] Taken to-
gether, each individual tumor is unique and carries a high level
of heterogeneity. Therefore, even the same type of tumor can re-
spond differently to the same therapy. Generally, heterogeneity
and plasticity in cancer raise a risk of partial response to a therapy,
when resistant cell populations stay unaffected and lead to tumor
regrowth.[39] This leads to a fact that even the presence of known
biomarkers does not guarantee full response to a therapy target-
ing those biomarkers.[26,40,41] For example, monoclonal antibod-
ies Panitumumab (Vectibix) and Cetuximab (Erbitux) targeting
EGFR, applied as a monotherapy in patients with EGFR-positive
tumors, yielded only about 10% of response rate.[40] Therefore,
it is important to be able to experimentally test sensitivity of a
tumour to anti-cancer compounds.
In vitro drug sensitivity and resistance test (DSRT) is per-
formed on cancer cells or tissues obtained from a patient with
a panel of anticancer compounds in order to experimentally
define sensitivity and resistance of each individual cancer. Uti-
lizing DSRT in combination with information from molecu-
lar profiling can provide a fuller picture about the nature of
disease allowing for finding more appropriate therapy in each
individual case. Moreover, testing tumor cells with a library of
anticancer compounds and their combinations can reveal sensi-
tivity of a tumor to compounds that are usually not prescribed
for this type of cancer, so-called drug repurposing.[42–44] Finally,
repeated test on tumor cells obtained from a patient after the ther-
apy, can identify resistant cells that were not eliminated with the
first therapy, and find compounds that can be effective against
them.[44]
Ex vivo tests on primary patient-derived tumor samples in-
clude xenograft models, tumor tissue slices, and 2D and 3D cell
culture models.[45,46]
1) In xenograft models, fresh pieces of tumor are implanted into
immunodeficient mice or chicken egg chorioallantoic mem-
brane (CAM) with a goal to follow the dynamics of tumor pro-
gression during and after treatment.[47,48] Xenograft models
are very important for pre- and co-clinical evaluation of an-
ticancer treatments.[49] However, there are some drawbacks
of xenograft models, which restrict their clinical applications
for making decisions about the appropriate therapy. First, the
success rate of establishing of a xenograft is low; second, the
time of establishing varies from 2 to 12 months; third, this
method is very costly and not compatible with high through-
put required in precision medicine.[45,47]
2) Tumor tissue slices are thin slices of a tumor that are tested
in microtiter plates with different compounds. The advantage
of this model is that tumor cells are preserved in their origi-
nal environment and their response to drugs can closely rep-
resent tumor response in vivo. The model is, however, only
limited to patients that undergo a surgery. Moreover, this is a
low throughputmethod limiting the number of possible com-
pounds and combinations that can be tested.[45,50]
3) In vitro 2D and 3D cell culture models are most promising to
be adopted for testing of patient-derived cells in clinics, due
to their compatibility with high throughput, possibility to be
performed within 2–3 days, and requirement of relatively low
cell numbers. Performing such in vitro sensitivity tests as a
routine in clinical practice will open a new era of precision
medicine in oncology and will help to navigate the decision
making toward successful therapy for each individual patient.
In this paper, we review studies describing in vitro DSRTs on
2D and 3D cell models based on patient-derived cells and dis-
cuss challenges and future steps needed for the adaptation of
these systems in clinics.
Despite the progress in sequencing and other “omic” analysis
techniques, it is still not possible to accurately predict response of
a particular patient to a therapy based on data of molecular pro-
filing. Therefore, experimental test (DSRT) performed on cancer
cells of the patient to elucidate individual sensitivity and resis-
tance to different therapies can help defining suitable treatment
for each patient, decreasing a risk of adverse effects, and devel-
opment of resistance to the therapy.
4. DSRT on 2D Cell Culture Models
First DSRT of patient-derived tumor material dates back to the
1950s.[23,51,52] A lot of studies conducting in vitro tests on tumor
cells from patients with leukemia and solid tumors were pub-
lished in the period from 1970s to 1990s.[23,53] At that time, be-
fore molecular profiling was established, such tests were the first
steps toward precision medicine in oncology. From early 2000s,
with developing of sequencing technologies, genomic and tran-
scriptomic profiling of tumors came forward.With a premise that
molecular profiling and targeted therapy would solve the prob-
lem of non-responding malignancies, DSRT was less frequently
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used. However, there is now more understanding that combina-
tion of both approaches can give the fuller picture about a profile
of an individual disease. In this review, we will mostly focus on
studies published after 2000.
DSRT on 2D cell culture models is performed on tumor cells
obtained ether from blood or bonemarrow of patients with blood
cancer or from pieces of solid tumors, which is usually dis-
integrated into single cell suspension before testing. Obtained
cells are plated in microtiter plates and treated with a range
of concentrations of anticancer compounds for 24 to 72 h de-
pending on cell type and read-out assay. Commonly, such as-
says are performed in 96-[27,54] or 384-well plates[21,43,55] using
50 000–200 000 or 5000–20 000 cells per well, respectively. Cy-
totoxicity of drugs is estimated either by evaluating the abil-
ity of the tumor cells to proliferate and form colonies, or by
counting the number of live and metabolically active cells per
well.[56] Colony-forming assay is based on evaluating the abil-
ity of cells to form colonies after 2–3 weeks on agar medium
culture.[57] Number of live cells can be estimated by measuring
cell metabolism using bulk solution methods such as the tetra-
zolium (MTT) assay,[54] CellTiter 96 AQueous One cell prolifera-
tion assay,[27,42] the fluorometric microculture cytotoxicity assay
(FMCA),[51,58] and CellTiterGlo assay.[21,43,44,59] The MTT assay is
a colorimetric assay that assesses cell metabolic activity by reduc-
ing the tetrazolium dye MTT by NAD(P)H-dependent cellular
oxidoreductase enzymes to form colored formazan.[60] CellTiter
96 AQueous One assay is similar to the MTT assay.
[60] FMCA is
based on measuring fluorescence, which is generated by hydrol-
ysis of fluorescein diacetate (FDA) by cell esterases.[61] CellTiter-
Glo assay measures the level of ATP produced by live cells us-
ing firefly luciferase.[62] Cell viability can be also quantified by
staining cells followed bymicroscopy.[55] Hoechst 33 342 and 4′,6-
diamidino-2-phenylindole (DAPI) are often used to stain cell nu-
clei and estimate total cell number.[63,64] There are a number of vi-
ability dyes available including CyQuant,[55] Calcein AM, and pro-
pidium iodide that can distinguish between live and dead cells.
Since majority of chemotherapeutic drugs induce apoptosis in
cells, staining apoptotic cells, for example, with Annexin V,[65]
which binds to phosphatidylserine externalized on outer mem-
brane during apoptosis, or using TUNEL assay,[66] which de-
tects damaged DNA in cells, are often used. Both of these meth-
ods are based on analysis of stained cells either by microscopy
or fluorescence-activated cell sorting (FACS). In addition, using
microscopy-based read-out opens possibilities for more in-depth
analysis of treated cell population. For example, performing im-
munostaining with antibodies against specific marker of can-
cer cells enables distinguishing between response of cancer and
healthy cells, identifying if drug is specific or generally toxic.[64]
5. DSRT of Blood Cancer
Studies on DSRT introduced in this review are summarized in
Table 1. Majority of these studies are focused on different types
of blood cancer.[21,22,27,42–44,54,55,58] The reason for this is relatively
large number of cells that can be obtained from bone marrow
biopsy or blood samples (between 104 and 107 from bonemarrow
biopsy;[67] and up to 106–107 cells from blood sample). This is also
reflected in the number of patients recruited in such studies, as
well as number of anticancer compounds that can be testedwith a
sample from a single patient (Table 1). There is a number of stud-
ies performing screenings on primary leukemia cells with large
panels of drugs containing from 50 to 450 compounds.[21,43,44,59]
Below are some examples of studies performing sensitivity and
resistance testing on cells from patients with blood cancers.
Larsson et al. tested cells obtained from blood and bone mar-
row of 44 patients with AML in 96-well plates against ten an-
ticancer compounds. Toxicity of compounds was estimated by
using FMCA. The results from DSRT was positively correlated
with patient response to tested compounds in clinic.[58] Yamada
et al. in their study used leukemic cells from 132 children with
AML and found correlation between clinical non-responders and
resistance of cells in vitro, as well as between subtypes of AML
according to French–American–British classification and sensi-
tivity of cells to particular drugs.[68] Maxson et al. in their study
combined sequencing of leukemia cells obtained from patients
with chronic neutrophilic leukemia (CNL) and atypical chronic
myeloid leukemia (CML) with drug sensitivity testing performed
on murine cells transduced with particular mutations. In vitro
test was performed against a small-molecule kinase inhibitor li-
brary combined with a library of small interfering RNAs. For es-
timation of cell sensitivity, primary-cell colonies-forming assay
was used.[22] The authors sequenced samples from 27 patients
and showed that 59% of patients carried activating mutations
in gene of colony stimulating factor 3 (CSF3R) resulting in in-
creased signaling through JAK kinases. The authors performed
DSRT on primary cells obtained from one patient with ruxili-
tinib. As expected frommutagenesis profiling, the cells were sen-
sitive to ruxilitinib treatment in vitro, which was confirmed by
strong positive response of this patient to ruxilitinid therapy.[22]
In a follow up study, Maxson et al. performed the screen on
primary cells from patients with AML and chronic myelomono-
cytic leukemia (CMML) against a panel of kinase inhibitors us-
ing CellTiter 96 AQueous One solution cell proliferation assay.
[69]
The outcome of functional screen was combined with data
obtained from genomic profiling of the same specimens. A
HitWalker algorithmwas used to find correlations betweenmuta-
tional and drug-sensitivity profiles. Using this methodology au-
thors were able to spot new correlations between mutations in
gene of kinase TNK2 and sensitivity to existing multikinase in-
hibitor dasatinib and TNK2 inhibitors XMD8-87 and XMD16-
5.[69] Tyner et al. experimentally defined sensitivity of tumor cells
from 151 leukemia patients against 66 small-molecule kinase
inhibitors.[27] For assessing cytotoxic effect of drugs they used
CellTiter 96 AQueous One solution cell proliferation assay. They
clearly demonstrated that in vitro drug sensitivity test predicted
the clinical response and even the development of drug resis-
tance. Obtained functional data on individual drug sensitivity
and known targets of tested kinase inhibitors were used to de-
velop an algorithm, which enabled prediction of patient sensitiv-
ity to kinases based on their genomic data.[27] Frismantas et al.
tested 60 anticancer compounds on 68 samples obtained from
acute lymphoblastic leukemia (ALL) patients using an imaging-
based cell viability readout. In this read-out cells were stained
with CyQUANT dye that stains nuclear DNA. Functional in vitro
testing was performed in parallel with targeted sequencing of
52 frequently mutated genes in ALL.[55] The authors found no
correlation between observed in vitro drug responses and data
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Table 1. A table summarizing published studies on DSRT organized by type of cancer, using 2D and 3D cell models and utilizing state-of-the-art platforms
and alternative miniaturized systems.
Type of cancer Number of cells
per well









Acute myeloid leukemia (AML) 50 000 96-Well plate FMCA 44 10 Predictive (78%) [58]
Acute myeloid leukemia (AML) 20 000 96-Well plate MTT assay 132 13 Predictive of short-term,




(CNL) and atypical chronic
myeloid leukemia (CML)
25 000 N/A Primary-cell
colonies-forming assay
1 1 Predictive [22]
Leukemia 50 000 96-Well plate CellTiter 96 AQueous One
solution cell
proliferation assay
151 66 Predictive (1 patient) [27]
Acute lymphoblastic leukemia
(ALL)
30 000 384-Well plate Imaging-based cell
viability readout
68 60 Predictive [55]
Leukemia and lymphoma of
B cell, T cell, and myeloid
origin
20 000 384-Well plate ATP-based CellTiterGlo
assay
246 63 Predictive [21]
Acute myeloid leukemia (AML) 10 000 384-Well plate ATP-based CellTiterGlo
assay
18 187 Predictive [44]
Solid tumors




Breast cancer 100 000 96-Well plate MTT assay 175 10 Predictive 47% [74]
Ovarian cancer 80 000 96-Well plate MTT assay 32 6 Not assessed [71]
Glioblastoma multiforme
(GM)
N/A N/A Flow cytometry-based
detection of apoptosis
40 30 Predictive 26% [63]
Gastric cancer using 100 000 96-Well plate MTT assay 435 7 Not assessed [75]
Ovarian adenocarcinomas 500 000 12-Well plate BH3 profiling 16 1 Predictive [76]
Chronic myeloid leukemia
(CML)
1 000 000 12-Well plate BH3 profiling 24 1 Predictive [76]




N/A N/A Apoptotic drug sensitivity
assay
















384-Well plate FMCA 100 14 Not assessed [83]
Ovarian and peritoneal cancer 2000–10 000 96-Well plate ATP-based CellTiterGlo
assay
4 240 Not assessed [124]
Miniaturized systems





17 1 Predictive [81]
(Continued)
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Table 1. Continued.
Type of cancer Number of cells
per well












3 2 Not assessed [88]
Pancreatic cancer 100 Droplet microfluidic
based
Detection of apoptosis by
measuring caspase-3
activity
4 10 Not assessed [87]
Chronic lymphocytic leukemia
(CLL)
100 Droplet-Microarray Imaging-based cell
viability readout
5 9 Not assessed Under
review
Breast cancer (CTCs) 1000 Imaging-based cell
viability readout
24 1 Not assessed [114]
3D cell models
Colorectal cancer 250 spheroids
per drug
Indi-Treat™ array Imaging-based cell
viability readout
5 4 Not assessed [98]
Head and neck squamous cell
carcinoma (HNSCC)






1 3 Not assessed [99]
Ovarian cancer 2500 96-Well plate Imaging-based cell
viability readout
>1 22 Not assessed [102]
Colon cancer 5000 384-Well plate CellTiter Glo assay 4 1 Not assessed [103]
1000–3000 96-Well plate CellTiter Glo assay 4 Predictive [104]
Colorectal and
gastroesophageal cancer
4500–6000 96-Well plate WST8 viability assay 71 55 Predictive [105]




5000 Microfluidic chip Caspase-Glo®3/7 assay 2 1 Not assessed [107]
Mesothelioma patients N/A Microfluidic chip Imaging-based cell
viability readout
2 4 Predictive [108]
Lung cancer N/A Microfluidic chip Imaging-based cell
viability readout
8 2 Not assessed [109]
from genetic profiling. Interestingly new sensitivities to com-
pounds were found through functional in vitro sensitivity assay.
A patient, whose cells showed unexpected sensitivity to dasatinib,
demonstrated complete response to this compound.[55]
Dietrich et al. conducted a large study profiling in vitro drug
sensitivity of cells obtained from 246 patients diagnosed with
blood cancers against a panel of 63 drugs in vitro using cell
viability ATP-based CellTiterGlo assay. Results of DSRT were
combined with genome, transcriptome, and DNA methylome
analysis (Figure 1).[21] The main goal of the study was to find
genotype–phenotype associations in order to better understand
the mechanism underlying drug sensitivity and resistance and
to be able to use such correlations to predict suitable therapy
based on genomic analysis. Their results demonstrated that pa-
tients with similar responses accurately clustered into groups of
similar mechanisms of action. They were able to predict clinical
outcome of the treatment based on in vitro sensitivity testing and
noted consistency between results of DSRT combined with data
from molecular profiling and clinical outcome.[21]
Pemovska et al. and Kulesskiy et al.[43,44,59] from the Finland
Institute of Molecular Medicine (FIMM) introduced the individ-
ualized systems medicine (ISM). The main goal of ISM was to
identify suitable cancer drug therapy for each patient.[44] ISM
includes the following parts: i) molecular profiling and in vitro
DSRT, ii) clinical implementation of therapies predicted to be ef-
fective, and iii) studying consecutive samples from the treated
patients to understand the basis of resistance.[44] In the work of
Pemovska et al., authors tested cells obtained from 28 patients
with AML against a panel of 187 anticancer compounds. Similar
to the study of Dietrich et al.,[21] the authors of this studywere able
to cluster patients into five groups according to their drug sen-
sitivity and found correlations of these groups with mutational
profiling. However, not all clusters defined by drug sensitivity
test correlated with mutations found from genomic profiling.
The authors demonstrated that DSRT was predictive of clinical
responses according to European LeukemiaNet response crite-
ria. In addition, they were able to spot development of drug resis-
tance and sensitivity after the treatment. Repeated DSRT on cells
obtained from one of the patients after the treatment showed that
cancer cells gained resistance to dasatinib and rapalogs and be-
came sensitive to certain tyrosin kinase inhibitors. Deeper inves-
tigation of a resistant sample demonstrated that resistance most
likely did not occur due to a novel genetic alteration, but devel-
oped due to the preselection of existed sub clones of cancer cells.
Thus, the authors were able not only successfully predict clini-
cal outcome based on DSRT, but also identified development of
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Figure 1. Scheme summarizing methods used in precision oncology on example of blood cancer. Combining functional drug response screening with
omics profiling allows for systematic query of drug response phenotypes, underlying molecular predictors, and pathway dependencies of leukemia and
lymphoma. Reproduced with permission.[21] Copyright 2018, American Society for Clinical Investigation.
resistance after the therapy.[44] In an article by Kulesskiy et al.,
the workflow of DSRT platform with 450 anticancer drugs on
patient-derived cells using the acoustic nano-dispenser was de-
scribed in details.[59] In the following work of Pemovska et al.,
authors performed DSRT on cells obtained from patients with
CML and Philadelphia-chromosome-positive (Ph1) ALL pa-
tients using 252 drugs.[43] With this comprehensive screening,
they defined axitinib as a selective BCR-ABL1(T315I) inhibitor
and demonstrated that it is effective in patients with BCR-
ABL1(T315l)-associated disease.[43]
Snijder et al. developed a concept of pharmacoscopy, which
is a methodology for ex vivo drug response profiling.[64] This
methodology is based on immunofluorescence, automated mi-
croscopy, and image analysis of biopsies cells introduced to an-
ticancer drugs in vitro. The main goal of pharmacoscopy is to
identify specific response of marker-positive malignant cells to
anticancer drugs. According to the study, pharmacoscopy could
predict the clinical response of 20 AML patients to initial therapy
with accuracy of 88.1%. In addition, this methodology was used
to profile 48 patients with aggressive hematological malignan-
cies, 17 of whom received the pharmacoscopy-guided treatment
resulted in partial and complete remissions. Pharmacoscopy is
evaluated in ongoing clinical trial at the moment.[64]
6. DSRT of Solid Tumors
DSRT on solid tumors is more challenging compared to blood
cancers due to limited number of cells available for the test and
a need for harsh enzymatic disintegration of a tumor. In most
studies, cells for in vitro tests were obtained after surgical
removal of the tumor. This restricts applicability of sensitivity
profiling only to patients undergoing surgery. Number of cells
usually obtainedwith non-invasive needle biopsy is about 500 000
to 1 000 000 cells.[70] Considering that big part of patient material
is used for other tests including pathology and genetic profiling,
there is not enough cellular material left for DSRT. This is re-
flected in a fact that only up to 30 compounds are usually tested
on each single patient sample with majority of studies evaluating
less than ten compounds per patient (Table 1).[51,71–73] There are
several examples of studies conducted on cells obtained from dif-
ferent types of solid tumors that are summarized in Table 1 and
described below.
Villman et al. tested cells obtained from tumor biopsies of 37
patients with breast cancer using FMCA.[51] The result of DSRT
obtained in vitro was then correlated with clinical outcome. The
authors demonstrated that in vitro test predicted in vivo response
with a sensitivity (correlation of in vitro test with drug sensitivity
in patients) of 89% and a specificity (correlation of in vitro test
with drug resistance in patients) of 53%. They also observed that
low drug resistance in vitro was strongly associated with longer
time of tumor progression.[51] Xu et al. investigated in vitro sen-
sitivity of breast cancer cells from 175 samples against ten anti-
cancer drugs using the MTT assay. The results obtained from 83
(47%) samples showed positive correlationwith clinical outcome,
which was assessed according to standard World Health Organi-
zation (WHO) criteria.[74] Brigulova et al. tested tumor cells from
32 patients with ovarian cancer against a panel of six anticancer
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compounds using the MTT assay.[71] Authors compared in vitro
sensitivity of tumor cells isolated from surgically removed pri-
mary tumors and tumor cells isolated from ascites of the same
patients. The ascites are abnormal accumulations of fluid in an
abdomen occurring with multiple types of cancer and containing
tumor cells infiltrating from original tumor site. Obtaining cells
from ascites is less invasive and painful for the patients, and pro-
tocol for cell isolation is easier to perform resulting afterward in
higher cell viability in vitro comparing to viability of cells isolated
from disintegrated solid tumors. Obtained results showed that,
except for paclitaxel, cells from both sources demonstrated iden-
tical dose-response to the tested drugs. This result shows possibil-
ity of performing sensitivity profiling on cells fromascites instead
of cells from the original tumor.[71] Iwadate et al. investigated
the feasibility of performingDSRT for patients with glioblastoma
multiforme (GM).[63] Cells obtained from 40 patients diagnosed
with GMwere tested against a panel of 30 anticancer compounds
using flow cytometry-based detection of apoptosis. Authors con-
cluded that prescribing chemotherapy for GB patients recom-
mended on results of in vitro sensitivity testing is reasonable,
although a larger study is required to draw final conclusion.[63]
Noguchi et al. analyzed large number of tumor samples isolated
from435 patients with gastric cancer.[75] Cells were obtained from
485 lesions including 415 primary tumors and 70 metastatic tu-
mors. Specimens of metastatic tumors were obtained from liver,
lymph nodes, ovaries, and malignant ascites. Interestingly, au-
thors noted that in vitro chemosensitivity of metastatic tumors
was lower compared to sensitivity of the primary tumors. In ad-
dition, tumor cells obtained from stage IV cancers were on aver-
age less sensitive to drugs in vitro compared to specimens from
stage I, II, and III cancers, which correlated with clinical observa-
tions. The authors compared the outcomes and predictability of
DSRT and clinicopathological findings, such as tumor differen-
tiation, macroscopic appearance, and depth of invasion. The au-
thors found no correlation between drug sensitivity of tumors in
vitro and their pathological characteristics, and concluded that it
is difficult to predict clinical sensitivity of a tumor based on patho-
logical analysis. Overall, it was concluded that in vitro sensitivity
test on both primary and metastatic tumors repeated during dis-
ease progression, is essential for defining a suitable chemother-
apy regiment for each individual patient.[75] Montero et al. in their
study suggested and investigated an interesting approach for pre-
dicting cancer response to chemotherapy by using BH3 profil-
ing of primary patient-derived cells pre-incubatedwith anticancer
compounds.[76] BH3 profiling is based on measuring of mito-
chondrial membrane potential (ΔΨm) by using fluorescent dyes
that produce ΔΨm dependent shifts in fluorescence.[77] Change
in mitochondrial membrane potential is caused by mitochon-
drial outer membrane permeabilization (MOMP) induced by in-
cubating compound-pretreated cells with BH3 peptides. BH3
peptides interact with BCL-2 family of proteins that regulate
commitment of the cell to mitochondria-dependent apoptosis
pathway. In other words, sensitivity of mitochondria to BH3 pep-
tides indicates initiation of apoptosis pathway in pretreated cells.
Such test can show sensitivity of tumor cells to chemotherapy
within 16 h instead of several days. The authors demonstrated
that BH3 profiling predicts chemotherapy response across many
cancer types and many agents. They also tested 16 primary ovar-
ian adenocarcinomas from surgical resection and found that
percentage of “priming” (or high sensitivity of mitochondria to
BH3 peptides) correlated with patient response to therapy in
clinic.[76] Cortese et al. developed an ex vivo chemotherapy drug
response assay (ChemoID),[78] based on assessing drug response
of Cancer Stem Cells, as well as bulk tumor cells in 96-well plates
using MTT assay.[79] The test was performed in certified labora-
tory. In addition, protocols for sample collection from the patients
and its preservation for international shipment were developed.
In this study, specimens from three patients with head and neck
cancer were analyzed.[79]
In an extended DSRT, not only sensitivity of tumor cells to an-
ticancer compounds can be tested, but also toxicity of the same
compounds to healthy cells of the body. From estimating of LC90
(lethal concentration of drug killing 90% of cell population) of
compounds for both tumor and healthy cells, so-called thera-
peutic index is derived, which corresponds to a ratio of LC90 of
normal cells to LC90 of tumor cells. Therapeutic index is usu-
ally utilized in drug development pipeline to estimate efficacy
and safety of drug candidate.[80] However, there are very few
studies demonstrating the importance of using therapeutic in-
dex to determine suitable drug and the window of its concentra-
tions, when it shows efficacy but not toxicity, for each individual
patient.[81–83] Bosanquet and Bell in their work tested tumor and
normal cells obtained from 59 patients with different types of
cancer including acute myeloid leukemia, non-Hodgkin’s lym-
phoma, and ovarian cancer.[81] In 73% of tested tumors with
purity of tumor cells being <90% after isolation, healthy cells
were tested in this mixed co-culture and distinguished from tu-
mor cells by morphology. In remaining 27% of tested speci-
mens, which were isolated with >90% of tumor cells, healthy
cells were isolated from blood of the same patient and incubated
with drugs separately. In Figure 2, sensitivity profiles of tumor
and healthy cells from one patient to caclophosphamide, fludara-
bine, and vincristine are shown. Caclophosphamide and fludara-
bine have unfavorable therapeutic index (0.3 and 1.07), because
these drugs show almost identical toxicity to tumor and healthy
blood cells. Vincristine, on the other hand, has favorable thera-
peutic index (169), because its dose-dependent effect on healthy
cells is shifted two orders of magnitude toward higher concen-
trations of the drug leaving wide concentration range, when it is
effective against tumor cells and not harmful for healthy cells.
In Figure 2b, the sensitivity profiles of tested patients against a
panel of anticancer compounds are plotted. The graph shows that
working concentrations of anticancer compounds vary drastically
between the patients. In addition, the window of concentrations
where the drug is effective against tumor and still not toxic to
healthy cells is very narrow or does not exist. The only way to
determine this window is by performing DSRT on both malig-
nant and normal cells. Unfortunately, most cytotoxic chemother-
apy is given at or near the phase I—determined maximum tol-
erated dose without distinguishing between individual patient
sensitivities. The authors have clearly demonstrated that know-
ing therapeutic index of a drug for each individual patient is
extremely important not only for defining the drug that is effi-
cient against individual tumor and not toxic to normal cells, but
also for identification of suitable concentration of a drug.[81] In
another work, Haglund et al. demonstrated the importance of
using tumor and toxicity panels together for predicting individ-
ual drug effects.[83] Authors have tested more than 100 tumor
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Figure 2. Comparison of dose-response of tumor and normal cells. a) Cell survival and calculation of therapeutic index in a previously treated patient
with mantle cell non-Hodgkin’s lymphoma. Upper panel: unfavorable therapeutic index for cyclophosphamide (mafosfamide in vitro). Middle panel:
therapeutic index of ≈1 for fludarabine. Lower panel: favorable therapeutic index for vincristine. b) Scatter of LC90s for tumor and normal cells. Circles,
tumor cell LC90s; triangles, normal cell LC90s; ar, cytarabine; cb, carboplatin; dox, doxorubicin; fl, fludarabine; maf, cyclophosphamide (mafosfamide
in vitro); vc, vincristine; vp, etoposide. Adapted with permission.[81] Copyright 2004, Old City Publishing, Inc.
samples from patients with solid and hematological tumors
along with assessment of normal tissue toxicity. They used lym-
phocytes (PBMC) from healthy donors to reflect hematological
toxicity and human epithelial and renal cell lines to reflect ep-
ithelial and renal toxicity, respectively. They were able to detect
drugs with wide and narrow therapeutic index, which correlated
with known side effects of these drugs in clinics.[83]
There is a substantial number of publications about DSRT
from the 1950s to our days, which shows importance of this
method for prediction of individual drug sensitivities and resis-
tance. Standard protocol for DSRT is performed in microtiter
plates requiring large number of patient cells. That is whymost of
the publications is focused on blood cancer, where high number
of patient cells can be obtained. Nevertheless, there are a num-
ber of publications on DSRT performed on solid tumor cells as
well, in which mostly small number of drugs can be tested. In
order to be able to test all tumor types with large drug libraries, it
is necessary to miniaturize DSRT using platforms alternative to
microtiter plates.
7. Miniaturized Systems for DSRT on 2D Cell
Culture Models
The problem of insufficient cell material available for DSRT can
be solved by using miniaturized platforms based on technolo-
gies alternative to microtiter plates. There are numerous studies
demonstrating utilization of such platforms for screening of live
mammalian cells, however few of them are focused on screen-
ing of patient-derived cells with a goal of defining appropriate
therapy for cancer patients.[67,84–87] Some examples of such stud-
ies are given below and summarized in Table 1.
Pak et al. developed a microfluidic-cis-coculture (MicroC3)
chip to investigate drug response of primary CD138+ multiple
myeloma (MM) cells isolated from 17 patients in co-culture with
CD138− tumor-companion mononuclear cells isolated from the
same patient. Anticancer drug bortezomib was used to evalu-
ate the system.[67,84] MicroC3 chip consists of an array of sep-
arated culturing units containing a central well and two side
chambers connected to the central well through channels that
allow for exchange of paracrine signals but prevent cell-to-cell
interaction. This system is operated by passive pumping and
needs only a pipette to operate. About 7500 tumor cells in
5 µL medium were seeded through an inlet port of the cen-
tral well, while healthy cells were introduced through an in-
let of the side chambers. The authors used statistical methods
to segregate patients into clinically responsive and nonrespon-
sive ones based on DSRT. Using a co-culture system, all 17
patients were segregated correctly judging by their clinical re-
sponse. Using a monoculture system, patients could be segre-
gated only with 65% accuracy showing that co-culture of tumor
cells with healthy cells from their microenvironment gives more
accurate estimation of clinical response.[67] Ma et al. developed
a microgap plate (MGP), a 96-well-formatted microfluidic plate
with built-in micro-gaps (Figure 3a) that enables trapping and
screening of only 1000 cells per experiment.[88] Cells are in con-
tact with large medium volumes and could be washed without
losing cell content even in case of suspension cells. The authors
evaluated the device on cancer cell lines as well as on primary
cells from breast cancer patients and demonstrated good con-
cordance between dose-response obtained on their platform and
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Figure 3. Miniaturized 2D cell culture systems. a) Schematic representation of microgap plate (MGP). Reproduced with permission.[86] Copyright 2014,
RSC. b) Microfluidic based chip for rapid identification of optimal drug combinations. Workflow for patient samples (top left panel). Barcoding system to
distinguish between different drug combinations (bottom right panel). Design of the chip. Sixteen syringes with aqueous samples are connected to the
inlets in the microfluidics chip via tubing (ten with compounds, two with medium to generate single drug and control samples, two for barcoding, one
for the cell suspension, one with Caspase 3 substrate to detect apoptosis). Other two inlets in the microfluidics chip are used for carrier oil (FC-40) and
mineral oil (right panel).). Reproduced with permission.[87] Copyright 2018, Springer Nature. c) Schematic representation of Droplet-Microarray platform
(top panel). Microscopy images of arrays of cells formed on Droplet-Microarray with spot sizes of 1, 0.5, and 0.35 mm. Reproduced with permission.[92]
Copyright 2016, SAGE Publications.
conventional 96-well plates.[88] Fujii et al. fabricated a microflu-
idic chip containing eight parallel channels.[85] The SH-10-TC
stomach cancer cells were introduced into the chip in the amount
of 10 000 cells in 10 µL. A gradient of 5-fluorouracil was gen-
erated by mixing two dilutions containing 0.1–9.8 mg mL–1 of
compound, achieving eight different concentrations in parallel
channels and using 1250 cells per concentration. Viability of
cells was estimated microscopically after 24 h by staining dead
cells with EthD-1. The authors observed clear concentration-
dependent effect of drugs on primary cells using their system.
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Correlation with clinical outcome was not assessed.[85] Eduati
et al. developed a miniaturized system for combinatorial screen-
ing of anticancer therapeutics based on a droplet microfluidic
platform (Figure 3b). Droplet microfluidics is based on the for-
mation of an emulsion of aqueous droplets in oil phase in
the microfluidic channel.[89] Such droplets are capable of trap-
ping live cells and can serve as a mini-reservoir for screening
applications.[89] The authors built a system capable of testing ten
drugs in all the pairwise combinations, in total 1100 samples,
in droplets containing single cells using 100 cells per group of
droplets (plugs) with the same drug combination and 20 plugs
per each drug combination (Figure 3b). To set apart all the com-
binations, they came up with a sequential barcoding system di-
viding each group of droplets inside a microfluidic chamber
with sequences of droplets with binary (high/low) concentra-
tions of the blue fluorescent dye (Figure 3b). For estimation of
drug toxicity, a rhodamine 110 (green fluorescent dye) conjugated
substrate of Caspase-3, an early marker of apoptosis, was encap-
sulated in each droplet with cells. To be able to verify the dilu-
tions of all reagents, Alexa Fluor 594 (orange-fluorescent dye)
was added to each droplet (Figure 3b, bottom left panel). Multi-
ple droplets for each drug combination were generated on a chip
following by barcoding of each droplet with fluorescent dye. Af-
terward droplets containing cells were incubated in a gas perme-
able tubing for 24 h. After incubation period, all the droplets were
passed through a detection system with three different excitation
lasers (375, 488, and 561 nm) to detect 1) barcodes definingwhich
drug composition is in the droplets, 2) Alexa Fluor 594 to moni-
tor reagent dilution, and 3) Caspase-3 activity to estimate level of
apoptosis. Using this system, authors could successfully perform
a screen with all 1100 combinations of anticancer compounds
using in total only 1 million cells obtained from four pancreatic
cancer patients demonstrating distinct responses of individual
patients.[87]
In our laboratory, we have developed a universal miniatur-
ized platform for screening applications based on arrays of
hydrophilic spots created on a superhydrophobic background
(Figure 3c).[90–92] Hydrophilic spots have usually round or square
shape and their diameter or side length can vary from 300 to
1000 µm. Due to the extreme differences in wettability between
hydrophilic and superhydrophobic areas, applying aqueous so-
lution onto such hydrophilic-superhydrophobic patterned sur-
face leads to spontaneous formation of arrays of homogeneous
nanoliter-sized droplets, each of which can serve as a nanoreser-
voir for cell experiments. The size of culturing volumes ranges
from 5 to 200 nL and can be adjusted to a particular application
(Figure 3c). Such Droplet-Microarrays are compatible with stan-
dard laboratory equipment including automated microscopes,
fluorescence scanners, and non-contact liquid dispensers for
compounds and cells. It is compatible with microscopy-based
read-out and related procedures including staining, fixation, and
immunofluorescence protocols. We have demonstrated the use
of Droplet-Microarrays for multiple screening application of ad-
herent and suspension cells, as well as for 3D cell culture.[91,93] In
a recent study, we performed a screen of nine compounds on only
100 patient-derived chronic lymphocytic leukemia (CLL) cells
per a 100 nL droplet. Dose responses obtained on the Droplet-
Microarray platform using microscopy-based read-out were in
good agreement with results obtained in 384-well plates using
both microscopy-based estimation of viability and CellTiter Glo
assay (manuscript in under review).
In majority of studies described above, the platforms utilize
microfluidic principle. Themain advantage of such systems com-
pared to microtiter plates is using on average about an order
of magnitude less cells and reagents for screening. In addition,
microfluidic systems allow for creating perfusion systems for
long cultivation times and possibility for convenient media ex-
change. The drawback of described setups is still limited (up
to 96) throughput of compounds that can be analyzed. Systems
based on droplet microfluidic principle open the possibilities to
go down to single cell and pico- to nanoliter volumes. However,
such systems can be limited in their throughput, or have to be
used with complex barcoding system. Open 2D array format plat-
forms such as Droplet-Microarray allow for using three orders of
magnitude less cells and compounds, are designed for short-term
(2-3 days) cultivation time, and enable scaling up the throughput
of compounds up to thousands per small area of standard micro-
scopic glass slide. All types of described miniaturized systems
carry different properties and can be applied for different appli-
cation requirements.
The main purposes of systems, alternative to the state-of-the-
art microtiter plates for screening of patient-derived cells in 2D
models are 1) miniaturization, which enables the use of an order
of magnitude less cells and reagents for screenings; 2) possibility
to create flexible perfusion systems for long cultivation times; and
3) higher throughput, which enables screenings of large libraries
of drugs. Majority of the described platforms are based on themi-
crofluidic principle, and enable miniaturization and creation of
customized and flexible culturing solutions; however, such sys-
tems are not always compatible with screening of large drug li-
braries. Open 2D array format platforms enable miniaturization
and high throughput. The choice of a platform for the test should
be defined by the aim of the experiment.
8. DSRT on 3D Cell Culture Models
In the past two decades, 3D cell culture has been picking up as
a model that more closely represents in vivo situation. Tumor
spheroids and organoids, also called organotypic multicellular
spheroids, are examples of most commonly used 3D cell mod-
els in oncology. Tumor spheroids are tight spherical aggregates
of tumor cells that are derived from self-organization of single
cells, which can be represented by cancer cell lines or patient-
derived cancer cells.[94] Tumor organoids, in oppose to spheroids,
are formed by mechanical or enzymatic disintegration of the
original tumor tissue into small fragments followed by culturing
these tumor fragments in extracellular matrix network, such as
Matrigel.[95]
Tumor spheroids are simple and reproducible in vitro model,
which, in comparison with 2D monolayer cell culture, exhibits
characteristics of a tumor including in vivo features such as
morphology, formation of a hypoxic core, production of extra-
cellular matrix (ECM), cell–cell interaction, and protein, as well
as gene expression patterns.[96] It was demonstrated in mul-
tiple studies that cancer cells cultured in vitro in 3D versus
2D respond differently to the drug treatment resembling closer
in vivo response.[97] Tumor spheroids take only few days to
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Figure 4. Microfluidic based systems for the isolation and testing of CTCs. a) Three-dimensional layout of a platform for CTC cluster assay (left panel).
Representative bright-field images of microwells comprising a negative and positive sample, scale bar, 100 mm, and Hoechst staining of cell clusters,
scale bar, 50 mm (right panel). Reproduced with permission.[114] Copyright 2016, The Authors, published by AAAS. b) Schematic representation of CTC-
iChip system for isolation of CTC cells from whole blood (left panel). SEM images of post-array (left) and asymmetric focusing units (right). Adapted
with permission.[116] Copyright 2013, AAAS.
form and can be a suitable model for DSRT, where spheroids
formed from freshly patient-derived cells are tested against
a panel of anticancer compounds. Some examples of stud-
ies utilizing spheroids for DSRT are presented below and in
Table 1.
Jeppesen et al. successfully formed spheroids from cells ob-
tained from 15 of total 18 patients (83% success rate) with col-
orectal cancer in Petri dishes coated with agarose.[98] Obtained
spheroids consisted mostly of epithelial cells with up to 5%
of fibroblast contamination and closely represented original tu-
mor in terms of morphology and protein expression patterns
(Figure 5a). After 3 days of culturing, spheroids were transferred
into 96-well plates coated with agarose and introduced to anti-
cancer compounds for another 7 days. Authors observed distinct
patterns of dose-response in spheroids obtained from five differ-
ent donors indicating maintenance of individual drug sensitiv-
ity profiles in spheroids during culturing period. Correlation of
DSRT results with clinical outcome was not discussed.[98] Hage-
mann et al. studied formation of spheroids from the PiCa cell
line, which was generated from primary carcinoma specimens
without enzymatic digestions of single cells.[99,100] Spheroids
were grown using two methods—1) the method of hanging
droplet, where cell aggregation is promoted by gravitational ac-
cumulation of cells in the water–air interface of droplets; and
2) ultra-low attachment plates (ULA), where cells are prevented
from attaching to the surface, which leads to cell aggregation. The
authors successfully formed spheroids using both methods and
demonstrated reduction of spheroid diameter by treating them
with cisplatin, 5-fluorouracil (5-FU), or radiation.[99]
Tumor organoids or organotypic multicellular spheroids is an
example of 3D cell culture model of a primary tumor tissue ob-
tained from fresh biopsies.[94] Since organoids are derived from
tumor fragments, they closely resemble the tissue that they orig-
inate from including cell heterogeneity and presence of different
cell types. Tumor organoids can be passaged, expanded, and cry-
opreserved similar to cell lines. They can be generated from fine-
needle aspirations or surgically removed tumor within few weeks
and used for molecular profiling of a tumor, as well as for indi-
vidualized therapeutic screening (pharmacotyping).[95,101] There
is an increasing number of studies where patient-derived tu-
mor organoids are used for DSRT and other precision medicine
studies, some of which are described below and summarized in
Table 1.
Jabs et al. compared effects of anticancer drugs on cell lines
derived from primary ovarian tumor cells cultured either in
2D monolayers or in 3D organoids.[102] Organoids were formed
for 10 days of culturing cells in Matrigel. The authors devel-
oped a DeathPro pipeline, which is a confocal microscopy-based
assay and image processing workflow to simultaneously as-
sess cell death and growth arrest. Cells were incubated with
Hoechst and propidium iodide, and both the total number of
cells and dead cells were monitored during the cultivation. The
authors performed a screen of 22 compounds and their com-
binations on both 2D and 3D cell models and concluded that
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Figure 5. 3D cell cultures established using patient derived material. (a) Immunostaining of spheroids and corresponding tumors from one patient for
epithelial cell marker EpCAM (red) and gastrointestinal epithelial marker cytokeratin 20 (green). Nuclei are stained with Hoechst (blue). Size bars =
50 µm. Reproduced under the terms of the CC-BY license.[98] Copyright 2017, The Authors, published by PLoS One. b) Workflow of establishment of
patient-derived organoid cultures in 384-well format (top panel). Confocal image analysis of patient-derived organoid cultures in 384-well format stained
for F-actin (phalloidin, red), Ki-67 (green), and DAPI (blue) illustrates the maximum intensity projection (J), an optical section of the surface (K), and the
DAPI-negative luminal compartment of the canter (L, M) of an organoid structure. Scale bar 50 µm (bottom panel). Reproduced with permission.[103]
Copyright 2016, SAGE Publishing.
drug-induced cell death was comparable, while drug-induced
growth arrest varied between 2D and 3D cell cultures.[102]
Boehnke et al. cultured organoids formed from tumor cells of pa-
tients with colon cancer.[103] Organoids were first cultured and ex-
panded inMatrigel droplets in 12-well plates for several weeks till
aggregates reached 800 µm in diameter. For the compound
screening, organoids were then disintegrated into single-cell
suspension and 5000 cells were seeded in 384-well plate in
Martrigel (Figure 5b, top panel). After 4 days, organoids were
formed (Figure 5b, bottom panel) and introduced to com-
pounds for 3 days. Toxic effect of the anticancer compounds was
estimated by measuring ATP content using luminescent based
assay. Established workflow was validated for its robustness and
reproducibility with organoids established from cells obtained
from four different donors.[103] Pauli et al. developed a combinato-
rial panel, where authors formed organoids from patient-derived
tumor cells and compared data from the whole exome sequenc-
ing (sequencing of all of the protein-coding genes in a genome,
called exome), in vitro drug sensitivity, and in vivo drug sensitivity
of xenografts derived from the formed organoids.[104] The authors
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collected overall 145 specimens, representing 18 different tumor
types. Organoids were successfully formed from 56 specimens
by culturing and passaging freshly isolated tumor fragments in
Matrigel. The main aims of that study were to identify optimal
therapy based on in vitro and in vivo tests and create a database
connecting drug sensitivity to genetic background. In vitro and in
vivo drug sensitivity tests were performed on organoids derived
from four patients by plating 1000–3000 cells in Matrigel in 96-
well plate and estimating drug effect by using luminescent-based
CellTiter Glo assay. Optimal therapy identified based on the re-
sults of in vitro tests was implemented for two patients. In both
cases the recommended therapy performed better compared to
the existing standard therapy, showing the importance of such
tests in predicting response in patients.[104] Vlachogiannis et al.
established a biobank of patient-derived organoids (PDOs) from
metastatic colorectal and gastroesophageal cancer patients.[105]
The authors demonstrated that phenotypic and molecular profil-
ing of established PDOs closelymatched the original tumor. They
compared ex vivo drug response of PDOs with xenograft mouse
models, as well as with clinical response in patients and demon-
strated that their methodology can predict clinical response with
100% sensitivity and 93% specificity.[105]
3D cell culture models, such as tumor spheroids and
organoids, based on patient-derived cells closer represent in vivo
situation in comparison to 2D cell models, therefore suchmodels
aremore physiologically relevant and predictive of drug response
in patients. Establishing such models, however, associated with
some practical hurdles and very often takes days or weeks to be es-
tablished. In context of clinical test, the advantages of physiolog-
ical relevance have to be balanced with cost and time of the test.
9. Miniaturized Systems for DSRT on 3D Cell
Culture Models
All previously described systems for fabrication and screening of
patient-derived 3D cell culture models were performed in Petri
dishes and microtiter plates format. This format is associated
with high consumption of reagents and especially cells, which
is critical when working with limited patient-derived material.
Miniaturized microfluidic-based platforms for fabrication and
screening of patient-derived 3D cell culture models are address-
ing these problems. In addition to miniaturization of assays,
implementation of microfluidic-based systems allows for the for-
mation of more complex tumor-on-a-chip systems that closely
represent in vivo situation. In such systems, it is possible to
combine 3D cultures from different organs, co-culture multi-
ple cell types, creating perfusion systems, and drug gradients.
These types of complex tumor-on-a-chip systems are reviewed
elsewhere.[106,107] Majority of such systems are developed and
evaluated on cancer cell lines and represent great models for
studying fundamental biological processes. In addition, tumor-
on-a-chip systems can be very useful in drug discovery pipeline,
for example, for toxicity assessment of new drug candidates.
However, these systems are rather complex for utilization in clin-
ics, where fast, simple, and miniaturized systems are preferable.
There are several studies describing simple microfluidic-based
systems for performing DSRT on patient-derived spheroids and
organoids.
In the work of Ruppen et al., a microfluidic chip contain-
ing multiple independent channels and micro-wells was created
(Figure 6a).[107] The system was evaluated with spheroids derived
frompatients with non-small cell lung adenocarcinoma asmono-
culture and co-culture with pericytes isolated from the same pa-
tient. Spheroids were formed from 5000 cells (Figure 6a, right
panel), incubated with cisplatin for 2 days, followed by toxic-
ity quantification by the measurement of caspase-3/7 activity.
The results showed that co-cultured spheroids were more re-
sistant to the therapy compared to monoculture spheroids.[107]
Mazzocchi et al. developed a microfluidic device consisting of
multiple independent channels opening into a culturing well in
the middle (Figure 6b).[108] Tumor cells from fresh tumor biop-
sies from two mesothelioma patients were cultured in these
wells incorporated in ECM-mimicking HA/gelatin-based hy-
drogel. Authors demonstrated formation of organoids in their
system, which maintained mesothelioma phenotype for exten-
sive period of time. Drugs were introduced through perfusion
channels and their effect was estimated by live/dead staining
using Calcein/ethidium homodimer-1 followed by confocal mi-
croscopy. The results demonstrated good agreement between the
sensitivity of organoids to anticancer drugs estimated in the mi-
crofluidic system and the clinical response of the patients.[108]
In another example, a device containing multiple independent
rows of five connected chambers for culturing cells and creating a
gradient of compounds along those chambers was developed.[109]
Three-dimensional cell cultureswere formed in chambers inCul-
trex BME (as a substitute for extracellular matrix) from tumor
and stroma cells of fresh lung cancer tissues obtained from eight
patients with lung cancer. Obtained 3D cell cultures were tested
against two anticancer drugs and their combinations. Percent-
age of apoptotic cells was defined by apoptotic-specific staining
followed by confocal microscopy. Obtained sensitivities profiles
were in good agreement with profiles obtained in 96-well plates
using MTT assay.[109]
The use of 3D cell cultures derived from patient materials for
identification of personalized anticancer therapy is a relatively
recent approach. There are few studies showing positive corre-
lation between DSRT performed on tumor spheroid/organoid
cultures and short-term clinical response of the patients.[108]
However, there is no study yet comparing long-term survival rate
of patients, treated with therapy recommended based on results
of DSRT and treated with conventional therapy.[101,110]
Circulating tumor cells (CTC) are cells that detach from orig-
inal solid tumor and enter blood circulation. They are very im-
portant for monitoring drug sensitivity of a tumor because of
two reasons. First, they represent a population of metastatic
cells that cause 90% of cancer deaths.[111] Second, blood sam-
pling is non-invasive and can be repeated during and after the
treatment to monitor tumor clone evolution and development of
drug resistance. The main challenge in studying CTCs is that
there are only 1–100 cells mL–1 of blood present in patients
with metastatic disease. There are studies describing isolation
of CTCs from the blood using microfluidic-based systems.[112]
The problem of screening these cells, however, persists, because
only few hundred to several thousand cells can be obtained from
a blood sample. In order to be able to perform comprehensive
screening of such small cell numbers, highly miniaturized plat-
forms have to be used. Bithi et al., for example, developed a
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Figure 6. Miniaturized 3D cell cultures designed for DSRT experiments. a) Perfusedmicrofluidic system for forming and screening of 3D tumor spheroids
developed by Ruppen et al.[107] Cells are loaded in the system using hydrostatic pressure and are trapped in the microwells by gravity (left panel). Top-
view picture of two microfluidic channels filled with red and yellow food dyes (middle panel top). Image of an epoxy mold with rounded micropillars,
representing the negative of the final channels. Scale bar 1200 µm. (middle panel bottom). Representative images of spheroids formed in microwells
after 3 days in culture. Scale bar corresponds to 250 µm (left panel). Reproduced with permission.[107] Copyright 2015, RSC. b) Microfluidic device for
forming and screening of organoids developed by Mazzocchi et al.[108] (left panel). In situ organoid patterning technique (middle panel): a microfluidic
chamber (i) is filled with a mixture (blue) containing hydrogel precursors, photoinitiator, and patient-derived tumor cells (ii), and then illuminated with
UV light through a photomask (gray) (iii). Exposed precursor is crosslinked into a hydrogel (dark blue), detaining cells within the region (iv), and non-
crosslinked gel is flushed form the chamber with clean PBS from the chamber (v). Finally, PBS is replaced with DMEM (red) (vi) for incubation (middle
panel). The total measurement set-up, featuring a low-volume, closed loop fluidic circuit for each organoid facilitated by a computer-controlled peristaltic
pump (right panel). Reproduced with permission.[108] Copyright 2018, Springer Nature.
pipette-basedmicrofluidic cell isolation (MCI) chip, which allows
for the formation of an array of trapped static droplets, containing
single cells or cell clusters, from 10 µL of cell suspension contain-
ing from 10 to 100 cells. Cells can be introduced to compounds
and screened using microscopy-based read-out directly on the
chip. The proof-of-concept study was performed onMCF-7 breast
cancer cell line and did not involve patient-derived CTC.[113]
Khoo et al. demonstrated an approach to test patient-derived
CTCs from whole blood with anticancer compounds without cell
pre-isolation within 2 weeks.[114] The authors developed a mi-
crofluidic device containing eight channels (for drug gradient
formation), each of which contained an array of oval cavities
with 100 µm major axis (Figure 4a, left panel). Nucleated cell
fraction fromwhole blood containing both CTCs andWBCswere
seeded into the channels. Ratio of CTCs toWBCs was from 1/100
to 1/1000, which translated in approximately one CTC per cav-
ity (Figure 4a, right panel). Since CTCs are rapidly proliferating
and forming 3D cell clusters in vitro, while WBCs do not, cluster
formation was an indication of presence of CTCs in blood sam-
ples. Therefore, cluster formation is an indication of presence
of malignant tumor in the body and correlates with bad prog-
nosis for the patient. As expected, there was no cluster forma-
tion observed in blood samples from healthy donors (Figure 4a,
right panel). Drug treatment was performed using only samples
positive for cluster formation. Viability of cells in clusters was
estimated using live/dead staining and microscopy. Clear dose-
responses of CTC clusters to anticancer compounds were ob-
tained by using this system.[114]
Another possibility to perform screening on isolated CTCs is
to expand them in vitro and establish a stable long-term cell
culture.[115] In the work of Ozkumur et al., authors used CTC-
iChip,[116] a microfluidic-based platform to separate CTCs from
the whole blood. Working principle of CTC-iChip is based ei-
ther on using positive selection, in which CTCs are isolated
on magnetic beads with anti-EpCAM antibodies, or negative se-
lection, in which the blood is depleted of leukocytes by using
magnetic beads with antibodies specific to common leukocyte
antigen CD45 and the granulocyte marker CD15 (Figure 4b).[116]
In the work of Yu et al., authors used this platform to isolate
cells from patients withmetastatic breast cancer and successfully
established cell lines from six patients. These cell lines were cul-
tured in non-adherent in vitro conditions forming 3D cell ag-
gregates. The authors performed sequencing analysis in parallel
with DSRT with a goal to find correlations in drug sensitivity and
genetic context of each individual patient.[117]
Miniaturized systems for DSRT on 3D cell culture models are
mostly based on microfluidic principle and along with miniatur-
ization and decreasing the number of cells needed for the test,
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allow precise spatial and geometric control of culturing vessels,
which is very important for the formation of 3D aggregates. Such
platforms also give possibility to form more complex perfusion
tumor-on-a-chip systems co-culturing several cell types, which
can make tests on patient-derived cells more predictive. At the
same time, most of these solutions are rather low throughput
and not compatible with screening of large drug libraries. There-
fore, the choice of the screening platform should be defined by
the type (type of cancer, number of drugs) and purpose of the test.
10. Acceptance of Individual Prognostic Tests by
Healthcare System
Precision medicine in oncology today includes molecular pro-
filing and DSRT. Molecular profiling includes either targeted
sequencing for known oncogenes or more complex profiling
covering genome, epigenome, transcriptome, and metabolome
analysis.
Targeted sequencing for known oncogenes is applied in clin-
ics to identify if patient carries known mutations in these
genes and will respond to a certain targeted therapy. There
are several panels of genes that were approved by FDA for
targeted sequencing.[118,119] Genome profiling is performed by
multiple companies, including Foundation Medicine, Caris Life
Science, Guardant Health, GenomeDx Biosciences, Intermoun-
tain Healthcare, Genomic Health, Trovagene, Varientyx, Invi-
tae, Paradigm, and has a cost of several thousand U.S. dollars.
Depending on diagnosis, the cost of such test may be covered
by some medical insurances, including Medicare in the United
States.[119]
The aim of more complex molecular profiling, covering ge-
nomic, epigenomic, proteomic, and metabolomics analysis, is to
identify known changes in those profiles that can correlate with
sensitivity of a tumor to a particular therapy. Mostly such pro-
filing is still performed for research purposes. It is not part of
clinical routine but can be performed privately by a patient as an
additional information that can help to find suitable treatment.
DSRT is used in addition to molecular profiling to test the sen-
sitivity of patient derived cancer cells to anticancer compounds
in vitro. There are a number of studies analyzing previously pub-
lished work on DSRT and its ability to predict clinical response
in patients. Literature published during the past four decades on
DSRT performed on >15 000 tumor patients demonstrate that
such tests can predict short-term sensitivity of tumor to a drug
with accuracy of 50–80%, and short-term resistance with accu-
racy of 80–100%.[73,120] In other words, if cells are sensitive to
a drug in vitro, the tumor will be sensitive to this drug in vivo
with probability of 50–80%; and if cells are resistant to a drug
in vitro, the tumor will be resistant to this drug in vivo with
probability of 80–100%. There are several randomized clinical
studies investigating if life expectancy of patients treated with
drugs recommended by these tests was different compared to life
expectancy of patients that were treated with conventionally pre-
scribed therapy. About 25–35% of clinical reports stated improve-
ment of patient survival by using recommendations based on
DSRT results.[23,121] Based on this statistics, DSRT is not over-
all recommended as a predictive test by the American Society
of Clinical Oncology.[122] In clinical practice, DSRT is offered by
some private companies, such as TherapySelect, ChemoFx assay,
and CorrectChemo assay. The cost of the test can reach several
thousand U.S. dollars and usually is not covered by insurance
companies. The majority of DSRTs are performed in research
laboratories inside hospitals and are used for research purposes
being utilized as a recommendation for drug therapy only for late
stage cancer patients, which did not respond to standard therapy.
At the moment, the only personalized test that is accepted in
clinics and covered by insurance is targeted sequencing, which
is recommended by the practitioner for certain types of cancer.
Full molecular profiling and DSRT are not mainstream accepted
prognostic tests and considered depending on the situation of the
patient. As a rule, usually such tests are not covered by medical
insurance.
11. Toward Acceptance of DSRT as a Prognostic
Test in Clinics
DSRT can significantly improve selection of individualized
therapies for each patient. However, at the moment it is not rec-
ommended as a predictive test and not applied in clinics as a com-
mon practice. There are a number of issues discussed below with
how DSRT is performed at the moment, which hinders it from
being established in clinics.
11.1. Only Few Drugs are Tested in DSRT
At the moment on average about ten drugs (with exception of
blood cancers) are tested in DSRT, which leaves out compounds
that might be effective against a tested tumor.[23] In addition, it is
important to test combinations of drugs in DSRT, since combina-
torial therapies are proven to bemore effective compared to drugs
applied as mono therapy.[123] In order to achieve this, the proto-
cols and platforms utilized for DSRT should be compatible with
high throughput and be highly miniaturized. Commonly used
microtiter plates have to be substituted by Lab-on-a-Chip tech-
nologies that enable parallel screening of hundreds to thousands
of different compound combinations on a single patient sample
in nanoliter (instead of microliter) volumes.
11.2. DSRT is Performed Only Once Before the Therapy
Inmajority of published studies, DSRT is performed once before
the therapy is introduced to a patient. In vitro test can predict a
short-term response of a tumor to a drug, because cells that are
in majority at the moment in the tumor are tested. However, due
to constant clonal evolution within a tumur, some cancer cells
that did not respond to the first therapy, might proliferate fur-
ther and cause a relapse of a disease. Multiple DSRTs before and
after the therapy will allow to spot drug sensitivity of new emerg-
ing cancer cell populations. This will help to adjust the therapy
throughout the treatment in order to completely eliminate can-
cer cells from the body. For this, taking the multiple biopsies
from patients before, during, and after the therapy, followed by
performing DSRT on cells isolated from these biopsies, should
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be introduce to clinical practice. One important prerequisite for
this practice to be adopted in clinics is low cost of DSRT test,
which can be achieved by highlyminiaturizing the test using Lab-
on-a-Chip technologies.
11.3. DSRT is Performed Only on Cells from Original Tumor
Usually DSRT is performed on cells from original tumor. How-
ever, it is critical to test cancer cells from metastatic locations as
well, because they represent the most dangerous cell population
causing 90% of death and might differ from the cells in original
tumor in their response to a therapy.[111] In addition, it is impor-
tant to perform DSRT in parallel on healthy cells in order to de-
fine individual therapeutic index of drugs. Knowing individual
therapeutic index of a drug for each patient is extremely impor-
tant not only for defining the drug that is efficient against indi-
vidual tumor and not toxic to normal cells, but also for identifica-
tion of suitable concentration of a drug for individual patient.[81]
In order to have an overview of all individual characteristics of
tumor and healthy cells for each patient, it is important to obtain
multiple samples of cells from different sites from the patient,
including cancer cells from the site of original tumor, metastatic
sites, CTCs, as well as healthy cells followed by performingDSRT
on each of these cell types. Considering the cost of the test and
that only minute number of cells can be obtained from CTCs or
metastatic site, DSRT test has to be highly miniaturized.
11.4. DSRT Requires Large Number of Cells
At themoment, DSRT is performed in 384- or even 96-well plates,
requiring from 5000 to 200 000 cells per well. This is the rea-
son why DSRT is only performed when relatively large number
of cells is available as in case of blood cancer or surgically re-
moved solid tumors. When cells are obtained with needle biopsy
from original tumor or metastatic sites, there is not enough cell
material available for DSRT. Using alternative miniaturized tech-
nologies that enable tests on low cell numbers in small volumes
can be a solution. For example, with 500 000 cells on average
obtained from needle biopsy, only 50 experiments can be per-
formed in 384-well plate (10 000 cells per well) and five in 96-well
plate (100 000 cells per well). By using only 100 cells per well,
it would be possible to perform 5000 experiments per each pa-
tient. Performing large screenings will increase number of drugs
and their combinations that can be tested for one patient, giv-
ing wider selection for the therapy. In order to achieve it, highly
miniaturized platforms that enable parallel screening of minute
number of cells in small (nanoliter) volumes have to be adopted
in clinical laboratories.
11.5. Most DSRTs are Performed on 2D Cell Cultures
Three-dimensional cell cultures are known to closer represent in
vivo cell environment compared to 2D cell models, which makes
them more suitable models for predicting drug responses in pa-
tients. There is a number of studies using 3D cell cultures for
DSRT.[102–104] However, most of the studies in DSRT were per-
formed using 2D cell culture models. The reasons for that are
that 3D cell models are more difficult to establish and analyse,
and in many cases, they require even more cells compared to 2D
cell culture. Platforms and methodologies that enable easy for-
mation and analysis of homogeneous spheroids and organoids
in single-per-well manner with low input of cells are absolutely
needed in order to establish DSRT on 3D cell culture as a test in
clinics.
11.6. DSRT is Not Standardized
At the moment, DSRT is performed mostly in the research lab-
oratories that work together with hospitals. Each laboratory uses
different experimental setup. Clinics that do not have excess to
such research facilities, do not have possibility to perform DSRT.
Companies that offer DSRT as a service are scarce and follow
different experimental setups as well. Standardization of DSRT
by defining standard and optimal formats (2D or 3D) and experi-
mental setup (platform, treatment time, read-out assay) is critical.
In order to be applied in clinics, DSRT should be robust, simple,
performed on minute amounts of cell material, and inexpensive.
11.7. Not Sufficient Evaluation of DSRT in Clinics
According to the published randomized clinical studies focus-
ing on predictability of DSRT for long-term survival of patients,
only about 25–35% claim positive influence of DSRT on defin-
ing suitable therapy for patients.[23,121] However, all the issues
stated above about how DSRTs are performed contribute to this
poor positive correlation rate. There is a clear need to address
these issues and perform more clinical studies investigating
whether choosing therapy for individual patients based on results
of DSRT has an influence on short- and long-term response of
patients to the therapy.[51]
There are a number of issues that need to be addressed in
order for DSRT to be accepted as a prognostic test for defining
anticancer treatment in clinics. The DSRT technology should be-
come compatible with: 1) low cell numbers; 2) high throughput;
3) physiologically relevant cell models; 4) multiple testing before
and after the therapy. 5) DSRT methods should be used on cells
originating from both original tumour and metastasis. The test
should be 6) standardized and 7) more clinical studies should
demonstrate the relevance of DSRT. In order to achieve these
goals, the protocols and platforms utilized for DSRT should be
compatible with high throughput, be highly miniaturized and
affordable. Commonly used microtiter plates have to be substi-
tuted by technologies that enable parallel screening of hundreds
to thousands of different compound combinations on a single
patient sample in nanoliter (instead of microliter) volumes. Tak-
ing multiple biopsies from patients before, during, and after the
therapy, as well as from different sites, including original tumor,
metastatic sites, CTCs, as well as healthy cells, followed by per-
forming DSRT on cells isolated from these biopsies, should be
introduced as a routine in clinical practice. It will take some time
till such tests will be optimized and standardized for clinical use.
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First clinical studies need to be performed to collect large data
sets and demonstrate that DSRT has a predictive value for differ-
ent types of cancer. Therefore, it is important to investigate dif-
ferent cancer types and stages, to test cells from different sites
of cancer and multiple times during treatment, and to moni-
tor short-term response, as well as long-term survival rates of
patients.
12. Concluding Remarks
Based on numerous DSRT studies and corresponding published
rates of prediction of short-term clinical response in patients, it
appears that DSRT is an important method that can help in pre-
diction of short- and eventually long-term responses of individual
cancer patients to a therapy. Using results obtained from DSRT
in combination withmolecular profiling data can help practition-
ers to have a more comprehensive picture of nature of individual
cancer, and to select a suitable therapy for each patient. There
are some challenges discussed in this review that have to be ad-
dressed in order for DSRT to be established as a routine test in
clinics. Considering high level of heterogeneity of cancer and the
fact that majority of patients do not respond to standard thera-
pies, it is absolutely necessary to personalize cancer treatment
and test tumor cells from individual patients for sensitivity and
resistance against anticancer drugs before the treatment. Intro-
ducing DSRT as a routine test for estimation of sensitivity and re-
sistance of tumour cells to a therapy before, during, and after the
therapy, in addition testing healthy cells of a patient for adverse
effects, can increase efficiency of a therapy, reduce side effects,
and lead to longer survival rates.
Acknowledgements
The work was supported by the ERC Starting Grant (ID: 337077-
DropCellArray), ERC-Proof-of-concept grant (ID: DLV-680913-
CellScreenChip), the Helmholtz Association’s Initiative and Networking
Fund (grant no. VH-NG-621), and EXIST Forschungtransfer “Aquarray”
03EFJBW155. The presentation of the author byline was adjusted on
February 13, 2020.
Conflict of Interest
The authors declare no conflict of interest.
Keywords
drug sensitivity and resistance test (DSRT), oncology, precision medicine
Received: June 7, 2019
Revised: October 1, 2019
Published online: January 16, 2020
[1] a) M. Wang, J. Zhao, L. Zhang, F. Wei, Y. Lian, Y. Wu, Z. Gong, S.
Zhang, J. Zhou, K. Cao, X. Li, W. Xiong, G. Li, Z. Zeng, C. Guo, J. Can-
cer 2017, 8, 761; b) H. Peinado, H. Zhang, I. R. Matei, B. Costa-Silva,
A. Hoshino, G. Rodrigues, B. Psaila, R. N. Kaplan, J. F. Bromberg, Y.
Kang, M. J. Bissell, T. R. Cox, A. J. Giaccia, J. T. Erler, S. Hiratsuka, C.
M. Ghajar, D. Lyden, Nat. Rev. Cancer 2017, 17, 302.
[2] C. R. UK, Cancer Research UK 2016
[3] G. B. D. Mortality, C. Causes of Death, Lancet 2016, 388, 1459.
[4] V. Malhotra, M. C. Perry, Cancer Biol. Therapy 2003, 2, 1.
[5] C. Sawyers, Nature 2004, 432, 294.
[6] a) V. Morris, S. Kopetz, F1000Prime Rep. 2013, 5, 11; b) S. Ryu, C.
Youn, A. R.Moon, A.Howland, C. A. Armstrong, P. I. Song,Chonnam
Med. J. 2017, 53, 173.
[7] S. R. Shah, T. L. Walsh, C. B. Williams, S. A. Soefje, J. Oncol. Pharm.
Pract. 2003, 9, 151.
[8] N. Iqbal, N. Iqbal,Mol. Biol. Int. 2014, 2014, 9.
[9] S.-F. Wong, Clin. Ther. 2005, 27, 684.
[10] a) S. Senapati, A. K. Mahanta, S. Kumar, P. Maiti, Signal Transduction
Targeted Ther. 2018, 3, 7; b) S. Hossen, M. K. Hossain, M. K. Basher,
M. N. H. Mia, M. T. Rahman, M. J. Uddin, J. Adv. Res. 2018, 15, 1.
[11] L. Brannon-Peppas, J. O. Blanchette, Adv. Drug Delivery Rev. 2004,
56, 1649.
[12] a) O. M. Kutova, E. L. Guryev, E. A. Sokolova, R. Alzeibak, I. V. Bal-
alaeva, Cancers 2019, 11, 68; b) Y. Matsumura, H. Maeda, Cancer
Res. 1986, 46, 6387.
[13] U. A. Kiernan, S. Naylor, Drug Discov. World 2018, 9, 9.
[14] N. A. Miliotou, C. L. Papadopoulou, Curr. Pharm. Biotechnol. 2018,
19, 5.
[15] M.-S. Lee, A. J. Flammer, L. O. Lerman, A. Lerman, Korean Circ. J.
2012, 42, 583.
[16] C. Reitz, Ann. Transl. Med. 2016, 4, 107.
[17] E. R. Pearson, Diabetic Med. 2016, 33, 712.
[18] M. Verma, J. Pers. Med. 2012, 2, 1.
[19] a) L. J. van ’t Veer, R. Bernards,Nature 2008, 452, 564; b) S. Hanash,
Nat. Rev. Cancer 2004, 4, 638; c) A. F. Rendeiro, C. Schmidl, J. C. Str-
efford, R. Walewska, Z. Davis, M. Farlik, D. Oscier, C. Bock, Nat.
Commun. 2016, 7, 11938; d) C. Schmidl, G. I. Vladimer, A. F. Ren-
deiro, S. Schnabl, T. Krausgruber, C. Taubert, N. Krall, T. Pemovska,
M. Araghi, B. Snijder, R. Hubmann, A. Ringler, K. Runggatscher, D.
Demirtas, O. L. de la Fuente, M. Hilgarth, C. Skrabs, E. Porpaczy,
M. Gruber, G. Hoermann, S. Kubicek, P. B. Staber, M. Shehata, G.
Superti-Furga, U. Jäger, C. Bock, Nat. Chem. Biol. 2019, 15, 232.
[20] a) N. L.-X. Syn, W.-P. Yong, B.-C. Goh, S.-C. Lee, Expert Opin. Drug
Metab. Toxicol. 2016, 12, 911; b) C. Le Tourneau, E. Borcoman, M.
Kamal, Nat. Med. 2019, 25, 711.
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